Links for Keyword: Movement Disorders
Follow us on Facebook and Twitter, or subscribe to our mailing list, to receive news updates. Learn more.
Walking backward may seem a simple task, but researchers don’t know how the mind controls this behavior. A study published online today in Science provides the first glimpse of the brain circuit responsible—at least in fruit flies. Geneticists created 3500 strains of the insects, each with a temperature-controlled switch that turned random networks of neurons on when the flies entered an incubator. One mutant batch of fruit flies started strolling in reverse when exposed to warmth (video, right panel), which the team dubbed “moonwalkers,” in honor of Michael Jackson’s famous dance. Two neurons were responsible for the behavior. One lived in the brain and extended its connections to the end of the ventral nerve cord—the fly’s version of a spine, which runs along its belly. The other neuron had the opposite orientation—it started at the bottom of the nerve cord and sent its messaging cables—or axons—into the brain. The neuron in the brain acted like a reverse gear in a car; when turned on, it triggered reverse walking. The researchers say this neuron is possibly a command center that responds to environmental cues, such as, “Hey! I see a wall in front of me.” The second neuron functioned as the brakes for forward motion, but it couldn’t compel the fly to moonwalk. It may serve as a fail-safe that reflexively prevents moving ahead, such as when the fly accidentally steps onto a very cold floor. Using the two neurons as a starting point, the team will trace their links to sensory neurons for touch, sight, and smell, which feed into and control the moonwalking network. No word yet on the neurons responsible for the Macarena. © 2014 American Association for the Advancement of Science
For years, some biomedical researchers have worried that a push for more bench-to-bedside studies has meant less support for basic research. Now, the chief of one of the National Institutes of Health’s (NIH’s) largest institutes has added her voice—and hard data—to the discussion. Story Landis describes what she calls a “sharp decrease” in basic research at her institute, a trend she finds worrisome. In a blog post last week, Landis, director of the $1.6 billion National Institute of Neurological Disorders and Stroke (NINDS), says her staff started out asking why, in the mid-2000s, NINDS funding declined for R01s, the investigator-initiated grants that are the mainstay of most labs. After examining the aims and abstracts of grants funded between 1997 and 2012, her staff found that the portion of NINDS competing grant funding that went to basic research has declined (from 87% to 71%) while applied research rose (from 13% to 29%). To dig deeper, the staffers divided the grants into four categories—basic/basic; basic/disease-focused; applied/translational; and applied/clinical. Here, the decline in basic/basic research was “striking”: It fell from 52% to 27% of new and competing grants, while basic/disease-focused has been rising (see graph). The same trend emerged when the analysts looked only at investigator-initiated grants, which are proposals based on a researcher’s own ideas, not a solicitation by NINDS for proposals in a specific area. The shift could reflect changes in science and “a natural progression of the field,” Landis writes. Or it could mean researchers “falsely believe” that NINDS is not interested in basic studies and they have a better shot at being funded if they propose disease-focused or applied studies. The tight NIH budget and new programs focused on translational research could be fostering this belief, she writes. When her staff compared applications submitted in 2008 and 2011, they found support for a shift to disease-focused proposals: There was a “striking” 21% decrease in the amount of funding requested for basic studies, even though those grants had a better chance of being funded. © 2014 American Association for the Advancement of Science.
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 1: Biological Psychology: Scope and Outlook
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 1: An Introduction to Brain and Behavior
Link ID: 19440 - Posted: 04.02.2014
By James Gallagher Health and science reporter, BBC News US doctors are warning of an emerging polio-like disease in California where up to 20 people have been infected. A meeting of the American Academy of Neurology heard that some patients had developed paralysis in all four limbs, which had not improved with treatment. The US is polio-free, but related viruses can also attack the nervous system leading to paralysis. Doctors say they do not expect an epidemic of the polio-like virus and that the infection remains rare. Polio is a dangerous and feared childhood infection. The virus rapidly invades the nervous system and causes paralysis in one in 200 cases. It can be fatal if it stops the lungs from working. There have been 20 suspected cases of the new infection, mostly in children, in the past 18 months, A detailed analysis of five cases showed enterovirus-68 - which is related to poliovirus - could be to blame. In those cases all the children had been vaccinated against polio. Symptoms have ranged from restricted movement in one limb to severe weakness in both legs and arms. Dr Emanuelle Waubant, a neurologist at the University of California, San Francisco, told the BBC: "There has been no obvious increase in the pace of new cases so we don't think we're about to experience an epidemic, that's the good news. BBC © 2014
By Katherine Harmon Courage Unless you’ve eaten sannakji, the Korean specialty of semi-live octopus, you might never have had a squirming octopus arm in your mouth. But you’ve most likely had a very similar experience. In fact, you’re probably having one right now. Octopus arms might seem strange and mysterious, but they are remarkably similar to the human tongue. Known as muscular hydrostats, both of these appendages can easily bend, extend and change shape (remember that time you had to stretch out your tongue to lick that last bit of chocolate pudding from the bottom of the cup?). Researchers are hoping a new interdisciplinary project to look at movement in the octopus arm and the human tongue will shed light on how both of these complex structures are activated. This, in turn, could help scientists understand neurological diseases that affect speech, such as Parkinson’s. “The human tongue is a very different muscular system than the rest of the human body,” Khalil Iskarous, an assistant professor of linguistics at the University of Southern California who is helping to lead the research, said in a prepared statement. “Our bodies are vertebrate mechanisms that operate by muscle working on bone to move. The tongue is in a different muscular family, much like an invertebrate. It’s entirely muscle—it’s muscle moving muscle.” Both move by compressing fluid in one section of a muscle, creating movement in another part. But we know little about exactly how that movement is initiated and so finely controlled. © 2014 Scientific American
Helen Shen To researchers who study how living things move, the octopus is an eight-legged marvel, managing its array of undulating appendages by means of a relatively simple nervous system. Some studies have suggested that each of the octopus’s tentacles has a 'mind' of its own, without rigid central coordination by the animal’s brain1. Now neuroscientist Guy Levy and his colleagues at the Hebrew University in Jerusalem report that the animals can rotate their bodies independently of their direction of movement, reorienting them while continuing to crawl in a straight line. And, unlike species that use their limbs to move forward or sideways relative to their body's orientation, octopuses tend to slither around in all directions. The team presented its findings on 10 November at the annual meeting of the Society for Neuroscience in San Diego, California. The new description of octopus movement is “not how one would imagine that would happen, but it seems to give a lot of control to the animal", says Gal Haspel, a neuroscientist at the New Jersey Institute of Technology in Newark. Haspel studies worm locomotion, and he was also surprised by the researchers’ report that the octopus pushes itself with worm-like contractions of its tentacles. Different combinations flex together to produce movement in different directions. Levy, who began the research as part of a project to design and control flexible, octopus-like robots, says that the work could also help to uncover basic biological principles of locomotion. Levy’s team deconstructed octopus movement using a transparent tank rigged with a system of mirrors and video cameras, in which they tested nine adult common octopuses (Octopus vulgaris). © 2013 Nature Publishing Group
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 6: Evolution of the Brain and Behavior
Related chapters from MM:Chapter 5: The Sensorimotor System
Link ID: 18936 - Posted: 11.16.2013
by Ashley Yeager The compound that gives mold its musty smell can cause changes in fruit flies’ brains that mimic those of patients with Parkinson’s disease. Scientists do not know the exact cause of Parkinson’s disease, but studies have shown that exposure to human-made chemicals may be a risk factor for developing the movement disorder. Now researchers have found that the chemical 1-octen-3-ol, which mold naturally emits, kills flies’ brain cells that transmit dopamine, a compound involved in controlling movement. The mold molecule also reduces dopamine levels in the flies’ brains. In experiments with human cells, the mold chemical also blocked the cells from taking in dopamine, researchers report November 11 in the Proceedings of the National Academy of Sciences. The results offer insight into cases of movement problems that doctors have associated with fungi exposure, the scientists say. © Society for Science & the Public 2000 - 2013
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 18911 - Posted: 11.12.2013
By JAMES GORMAN SEATTLE — To hear Michael Dickinson tell it, there is nothing in the world quite as wonderful as a fruit fly. And it’s not because the fly is one of the most important laboratory animals in the history of biology, often used as a simple model for human genetics or neuroscience. “I don’t think they’re a simple model of anything,” he says. “If flies are a great model, they’re a great model for flies. “These animals, you know, they’re not like us,” he says, warming to his subject. “We don’t fly. We don’t have a compound eye. I don’t think we process sensory information the same way. The muscles that they use are just incredibly much more sophisticated and interesting than the muscles we use. “They can taste with their wings,” he adds, as his enthusiasm builds. “No one knows any reason why they have taste cells on their wing. Their bodies are just covered with sensors. This is one of the most studied organisms in the history of science, and we’re still fundamentally ignorant about many features of its basic biology. It’s like having an alien in your lab. “And,” he says, pausing, seeming puzzled that the world has not joined him in open-mouthed wonder for his favorite creature, “they can fly!” If he had to define his specialty, Dr. Dickinson, 50, who counts a MacArthur “genius” award among his honors, would call himself a neuroethologist. As such, he studies the basis of behavior in the brain at the University of Washington, in Seattle. In practice he is a polymath of sorts who has targeted the fruit fly, Drosophila melanogaster, and its flying behavior for studies that involve physics, mathematics, neurobiology, computer vision, muscle physiology and other disciplines. © 2013 The New York Times Company
Lying in bed, unable to move a muscle, so-called locked-in patients have few ways to communicate with the outside world. But researchers have now found a way to use the widening and narrowing of the pupils to send a message, potentially helping these patients break the silence. Doctors use the constriction of pupils under bright light to test whether a patient’s brain stem is intact. But our pupils also show the opposite response—dilation—based on our thoughts and emotions, says Wolfgang Einhäuser, a neurophysicist at Philipps University of Marburg in Germany. Einhäuser had been struggling to interpret changes in pupil size during decision-making when he began to wonder about a different application. He contacted Steven Laureys, a member of the Coma Science Group at the University Hospital of Liège in Belgium, to explore how the pupil could be used to communicate a choice. Laureys works with locked-in patients, who have normal mental acuity but are paralyzed and unable to express thoughts to those around them. Many can control only the muscles that move their eyes; some, not even that. They can learn to communicate using EEG technology, in which electrodes on the scalp detect changes in brain activity. But applying the electrode cap is time-consuming, and the equipment is expensive, Einhäuser says. “If you imagine doing that every day, basically to communicate, that’s troublesome.” To find a different technique, Einhäuser, Laureys, and colleagues reached back in time. “The pieces have been there since the early ’60s,” Einhäuser says. A 1964 study showed that our pupils dilate when we perform mental arithmetic, like attempting to multiply 27 and 15 with no pencil and paper, and that harder tasks led to more dramatic dilation. The team set up a camera and a laptop to explore this automatic response. © 2012 American Association for the Advancement of Science.
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 18: Attention and Higher Cognition
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 14: Attention and Consciousness
Link ID: 18466 - Posted: 08.06.2013
Brendan Maher Hugh Rienhoff says that his nine-year-old daughter, Bea, is “a fire cracker”, “a tomboy” and “a very sassy, impudent girl”. But in a forthcoming research paper, he uses rather different terms, describing her hypertelorism (wide spacing between the eyes) and bifid uvula (a cleft in the tissue that hangs from the back of the palate). Both are probably features of a genetic syndrome that Rienhoff has obsessed over since soon after Bea’s birth in 2003. Unable to put on much muscle mass, Bea wears braces on her skinny legs to steady her on her curled feet. She is otherwise healthy, but Rienhoff has long worried that his daughter’s condition might come with serious heart problems. Rienhoff, a biotech entrepreneur in San Carlos, California, who had trained as a clinical geneticist in the 1980s, went from doctor to doctor looking for a diagnosis. He bought lab equipment so that he could study his daughter’s DNA himself — and in the process, he became a symbol for the do-it-yourself biology movement, and a trailblazer in using DNA technologies to diagnose a rare disease (see Nature 449, 773–776; 2007). “Talk about personal genomics,” says Gary Schroth, a research and development director at the genome-sequencing company Illumina in San Diego, California, who has helped Rienhoff in his search for clues. “It doesn’t get any more personal than trying to figure out what’s wrong with your own kid.” Now nearly a decade into his quest, Rienhoff has arrived at an answer. Through the partial-genome sequencing of his entire family, he and a group of collaborators have found a mutation in the gene that encodes transforming growth factor-β3 (TGF-β3). Genes in the TGF-β pathway control embryogenesis, cell differentiation and cell death, and mutations in several related genes have been associated with Marfan syndrome and Loeys–Dietz syndrome, both of which have symptomatic overlap with Bea’s condition. The mutation, which has not been connected to any disease before, seems to be responsible for Bea’s clinical features, according to a paper to be published in the American Journal of Medical Genetics. © 2013 Nature Publishing Group,
by Mara Hvistendahl and Martin Enserink A mysterious group of viruses known for their circular genome has been detected in patients with severe disease on two continents. In papers published independently this week, researchers report the discovery of agents called cycloviruses in Vietnam and in Malawi. The studies suggest that the viruses—one of which also widely circulates in animals in Vietnam—could be involved in brain inflammation and paraplegia, but further studies are needed to confirm a causative link. The discovery in Vietnam grew out of a frustrating lack of information about the causes of some central nervous system (CNS) infections such as encephalitis and meningitis, which can be fatal or leave lasting damage. "There are a lot of severe cases in the hospitals here, and very often we can't come to a diagnosis," says H. Rogier van Doorn, a clinical virologist with the Oxford University Clinical Research Unit in the Hospital for Tropical Diseases, Ho Chi Minh City. Extensive diagnostic tests turn up pathogens in only about half of patients with such infections, he says. Van Doorn and colleagues in Vietnam and at the University of Amsterdam's Academic Medical Center hoped that they might uncover new pathogens using a powerful new technique called next-generation sequencing. The group sequenced all the genetic material in cerebrospinal fluid (CSF) samples taken from more than 100 patients with undiagnosed CNS infections. One sample batch returned a promising lead: a viral sequence belonging to the Circoviridae family. © 2010 American Association for the Advancement of Science
The paralyzing syndrome Guillain-Barré syndrome isn't linked to receiving common vaccines, according to a U.S. study. Concerns about the association of Guillain-Barré syndrome with vaccines have "flourished" since there was a hint of an increased risk after the 1976 swine flu vaccine campaign. It hasn’t been clearly linked since then. The syndrome is an acute inflammatory disease that results in destruction of a nerve’s myelin sheath and some nerves, which in severe cases can progress to complete paralysis and even death. Researchers from the U.S. Centers for Disease Control and Prevention and Kaiser Permanente Vaccine Study Center in Oakland, Calif. looked back at cases of GBS over 13 years in the state that were confirmed by a neurologist who reviewed the medical records. In the 13-year study period 415 patients were confirmed with GBS only 25 had received a vaccine within six weeks before onset of the disease. "In summary, this study did not find any association between influenza vaccine or any other vaccine and development of GBS within six weeks following vaccination," Dr. Roger Baxter, co-director of the Kaiser Permanente Vaccine Study Center and his co-authors concluded in Monday's online issue of Clinical Infectious Diseases. © CBC 2013
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 15: Emotions, Aggression, and Stress
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 11: Emotions, Aggression, and Stress
Link ID: 18306 - Posted: 06.25.2013
By ALLISON HERSH LONDON I’M in line at the supermarket holding three items close to my chest. But I might as well be juggling my Kleenex box, toothpaste tube and an orange. Because — as you’d surely notice if you were behind me in line — I‘m bent forward at a sharp angle, which makes holding things difficult. I know you don’t want to stare, but you do. Maybe you think you’re being considerate when you say, apropos of nothing, “You look like you’re in pain.” Well, thanks, I am — but I’ll resist replying the way I want (“You look like you’re having a bad hair day”). I’m sorry. I know you mean well. Anyway it’s my turn at the register which means I’m closer to being at home where I can lie down and wait for the spasms to subside. Besides, if I told you what my issue was, you would probably shrug and reply that you’d never heard of it. There aren’t any public service announcements about it or telethons. No Angelina Jolies to bravely inform the world. Just people like me, in supermarket checkout lines. And this, I realize, is at the core of a problem that extends beyond me and my condition and that affects the way all of us respond to illnesses, some of which are the subject of public attention — and resources — and some of which are not. I have dystonia, a neurological disorder. Some years ago, for reasons no one knows, the muscles in my back and neck began to spasm involuntarily; the spasms multiply quickly, fatigue the muscles and force the body into repetitive movements and awkward postures like mine. There is no cure, only treatment options like deep brain stimulation, which requires a surgery I underwent last year as a last resort. © 2013 The New York Times Company
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 8: General Principles of Sensory Processing, Touch, and Pain
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 5: The Sensorimotor System
Link ID: 18171 - Posted: 05.20.2013
Voluntary movements involve the coordinated activation of two brain pathways that connect parts of deep brain structures called the basal ganglia, according to a study in mice by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health. The findings, which challenge the classical view of basal ganglia function, were published online in Nature on Jan. 23. “By improving our understanding of how the basal ganglia control movements, these findings could aid in the development of treatments for disorders in which these circuits are disrupted, such as Parkinson’s disease, Huntington’s disease and addiction,” says NIAAA Acting Director Kenneth R. Warren, Ph.D. The predominant model of basal ganglia function proposes that direct and indirect pathways originating in a brain region called the striatum have opposing effects on movement. Activity of neurons in the direct pathway is thought to promote movement, while activity in the indirect pathway is thought to inhibit movement. Newer models, however, suggest that co-activation of these pathways is necessary to synchronize basal ganglia circuits during movement. “Testing these models has been difficult due to the lack of methods to measure specific neurons in the direct and indirect pathways in freely moving animals,” explains first author Guohong Cui, Ph.D., of the NIAAA Laboratory for Integrated Neuroscience (LIN). To overcome these difficulties, Dr. Cui and colleagues devised a new approach for measuring the activity of neurons deep within the brain during complex behaviors. Their technique uses fiber optic probes implanted in the mouse brain striatum to measure light emissions from neurons engineered to glow when activated.
By Sandra G. Boodman, For the first decade of his life, every doctor who saw Jack DeWitt inevitably zeroed in on the harrowing circumstances of his premature birth. Delivered by emergency Caesarean section in December 1999, doctors universally ascribed his developmental problems to his being born six weeks early, said his mother, Ruth DeWitt. “It always came back to that.” When Jack’s walking became odd at age 5, doctors chalked it up to a mild form of cerebral palsy that can occur in children born too soon. “We were okay with it,” his mother said, because mild cerebral palsy would not “affect the length of his life or his enjoyment of it.” Jack’s parents were also reassured by his ability to catch up; with help, he mastered various skills: jumping, walking and writing in cursive. But by age 10, when his ability to walk badly deteriorated, a reevaluation by his doctors resulted in a very different diagnosis and prognosis. “We had all those years of feeling that he was a normal, healthy kid with some challenges,” his mother recalled. Discovering what was really wrong has been a heavy blow, magnified by Jack’s perceptive awareness of its implications. Ruth DeWitt, who lives with her family in Howell, Mich., outside Ann Arbor, was in the hospital undergoing a test for preeclampsia, or pregnancy-induced hypertension, when she began hemorrhaging, a sign of placental abruption. The life-threatening condition occurs when the placenta prematurely detaches from a woman’s uterus. Rushed into surgery, Jack was born weighing 3 pounds, 9 ounces, and was transferred to the neonatal intensive care unit at the University of Michigan Medical Center. Small but strong, he needed oxygen but no ventilator, and he came home 15 days later. © 1996-2012 The Washington Post
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 13: Memory, Learning, and Development
Link ID: 17615 - Posted: 12.18.2012
By ANDREW POLLACK An experimental drug preserved and even improved the walking ability of boys with Duchenne muscular dystrophy in a clinical trial, raising hopes that the first effective treatment for the disease may be on the horizon. Boys with the disease who received the highest dose of the drug had a slightly improved ability to walk after 48 weeks of treatment, the drug’s developer, Sarepta Therapeutics, announced Wednesday. By contrast, the boys who received a placebo suffered a sharp decline in how well they could walk. The drug, called eteplirsen, also appeared to restore levels of the crucial protein that muscular dystrophy patients lack to about half of normal levels, Sarepta said. “I think this changes the entire playing field for muscular dystrophy,” said Dr. Jerry R. Mendell, director of the gene therapy and muscular dystrophy programs at Nationwide Children’s Hospital in Columbus, Ohio, and the lead investigator in the trial. There are many caveats. The trial had only 12 patients, with only four receiving the high dose and four the placebo, and the data has not been reviewed by experts. It is also unclear how long the effects of the drug would last or if safety issues would arise with longer treatment. Also, eteplirsen would be appropriate for only about 13 percent to 15 percent of Duchenne patients, those with the particular genetic mutation the drug is meant to counteract. However, a similar approach might work for some other mutations. © 2012 The New York Times Company
by Jessica Hamzelou When something goes wrong in your brain, you'd think it would be a good idea to get rid of the problem. Turns out, sometimes it's best to keep hold of it. By preventing faulty proteins from being destroyed, researchers have delayed the symptoms of a degenerative brain disorder. SNAP25 is one of three proteins that together make up a complex called SNARE, which plays a vital role in allowing neurons to communicate with each other. In order to work properly, all the proteins must be folded in a specific way. CSP alpha is one of the key proteins that ensures SNAP25 is correctly folded. Cells have a backup system to deal with any misfolded proteins – they are destroyed by a bell-shaped enzyme called a proteasome, which pulls the proteins inside itself and breaks them down. People with a genetic mutation that affects the CSP alpha protein – and its ability to correctly fold SNAP25 – can develop a rare brain disorder called neuronal ceroid lipofuscinosis (NCL). The disorder causes significant damage to neurons – people affected gradually lose their cognitive abilities and struggle to move normally. To find out what role proteasomes might play in NCL, Manu Sharma and his colleagues at Stanford University in California blocked the enzyme in mice that were bred to lack CSP alpha. "We weren't sure what would happen," says Sharma. Either the misfolded SNAP25 would accumulate and harm the cells, or some of the misfolded proteins may work well enough to retain some of their function. © Copyright Reed Business Information Ltd.
by Nicola Guttridge Whether a tree branch or a computer mouse is the target, reaching for objects is fundamental primate behaviour. Neurons in the brain prepare for such movements, and this neural activity can now be deciphered, allowing researchers to predict what movements will occur. This discovery could help us develop prosthetic limbs that can be controlled by thought alone. To find out what goes on in the brain when we reach for things, biomedical engineers Daniel Moran and Thomas Pearce at Washington University in St Louis, Missouri, trained two rhesus macaques to participate in a series of exercises. When the monkeys reached for items, electrodes measured the activity of neurons in their dorsal premotor cortex, a region of the brain that is involved in the perception of movement. The monkeys were trained to reach for a virtual object on a screen to receive a reward. In some tasks the monkeys had to reach directly for an object, in others they had to reach around an obstacle to get to the target. Impulsive grab Moran and Pearce managed to identify the neural activity corresponding with several aspects of the planned movement, such as angle of reach, hand position and the final target location. The findings could one day allow the design of prosthetic limbs that can be controlled with thought alone, which is "one of the reasons we did the study", says Moran. © Copyright Reed Business Information Ltd.
By Scicurious Think about what happens when you walk. Really THINK about it. What does it take to walk? Well, your feet and legs have to move (far more complicated than they look), which means your muscles have to move, which means your nerves have to control your muscles, which means your brain has to send the signals in the first place. All of this is based on further information, knowing where you are in space and where you’re going, how fast you need to get there. And then there’s even more! How do you know where you are? How do you know how fast you’re going? How do you know which direction you’re headed? And behind all of this are thousands and millions of neurons firing, together and separately. And underlying THAT are thousands of biochemical processes which allow the neurons to fire… …now take that walking speed, and make it a run. The sheer number of neurobiological processes and number of things that need to happen to make you walk into your workplace every morning is the kind of thing that makes neuroscientists stop in their tracks with wonder. And today, we’re going to talk about a paper that may have worked out a tiny piece of how the brain might deal with things like increased speed. How does your brain keep up with your feet? By running a little faster. To understand how this works. We need to talk about two major things: place neurons, and oscillatory networks. © 2012 Scientific American
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 18: Attention and Higher Cognition
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 14: Attention and Consciousness
Link ID: 17059 - Posted: 07.18.2012
By Sandra G. Boodman, Liisa Ecola lay on the sofa in the living room of her Capitol Hill home counting the hours until she could see a specialist who, she fervently hoped, would tell her why she could no longer keep her eyes open. For several months, the 42-year-old transportation policy researcher for Rand had been squinting, even in the dark. Her puzzled optometrist had suggested she consult a neuro-ophthalmologist, a doctor who specializes in diseases of the eye originating in the central nervous system. Ecola had waited weeks to get an appointment, which was scheduled for Dec. 15, 2010. But the day before, Ecola recalled, “I opened my laptop and my eyes snapped shut.” To her horror, she discovered that her eyes would stay open only for a few minutes at a time. Panicked, she called the specialist to confirm the appointment, only to discover that she wouldn’t be seeing him at all. The office had no record of her. “I was really scared,” said Ecola, who called it the lowest moment in her quest for a diagnosis. “I was convinced I had a brain tumor.” Her problem turned out to be far less serious and far more easily treated. The following day she lucked into an appointment with another specialist, who explained the odd constellation of symptoms that had left her unable to leave her house. For several years, Ecola had suffered an unexplained, intermittent facial tic, in which she scrunched up her face as if she were tasting something awful. Because it seemed linked to stress, Ecola consulted a behavioral therapist in an effort to banish it through habit reversal training — using relaxation exercises and making a conscious effort to stop the tic. Until early 2010, the treatment usually worked, and Ecola seemed able to control it. © 1996-2012 The Washington Post
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 10: Vision: From Eye to Brain
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 7: Vision: From Eye to Brain
Link ID: 16696 - Posted: 04.24.2012
By LISA SANDERS, M.D., Columnist On Thursday, we challenged Well readers to figure out the diagnosis for a 27-year-old woman with an odd walk and slowly progressive weakness of her hips and thighs. The correct diagnosis is… Adult-onset Tay-Sachs disease The first person to get it right was Jason Maley, a third-year medical student at Tulane University. His answer came in just after 1 a.m., an hour after the case was posted. He says that all the clues were there; he just had to put it all together. He’s planning to go into internal medicine. (I certainly hope that he will!) Tay-Sachs is an inherited disease in which the inability to get rid of discarded parts of the cell membrane causes the death of certain nerve cells. There are several forms of the disease. The most common affects infants. Babies born with this version of the disease usually die by age 4. Another form of the disease affects children who usually die before reaching adulthood. Late-onset Tay-Sachs, the form of the disease this patient has, doesn’t manifest itself until adolescence or young adulthood and causes a slow loss of strength and coordination. While the form seen in children was first described over a century ago, this version wasn’t recognized until the 1970s. Patients with this form of the disease can get rid of some but not all of the fatty components of the cell wall and so have a much slower rate of cell death and disability. The degree of disability varies widely in this group, and there are patients who have the disease but appear to be completely asymptomatic. For many with this disease, life expectancy is normal, but most eventually require a wheelchair. © 2012 The New York Times Company